Aspirin use is associated with a 26% raised risk of heart failure in people with at least one predisposing factor for the condition.
People with cardiovascular disease (CVD) taking aspirin to lower their chances of suffering a heart attack or stroke experienced similar health benefits, including reduced death and hospitalization for heart attack and stroke, whether they took a high or low dose of aspirin, according to a study presented today at ACC.21, the American College of Cardiology’s 70th Annual Scientific Session and published in the New England Journal of Medicine.
For some patients, adding aspirin to a direct oral anticoagulant is an equation that rarely adds up.
George Washington University researchers found low dose aspirin may reduce the need for mechanical ventilation, ICU admission and in-hospital mortality in hospitalized COVID-19 patients. Final results indicating the lung protective effects of aspirin were published today in Anesthesia & Analgesia.
Hospitalized COVID-19 patients who were taking a daily low-dose aspirin to protect against cardiovascular disease had a significantly lower risk of complications and death compared to those who were not taking aspirin, according to a new study led by researchers at the University of Maryland School of Medicine (UMSOM).
Simpler phenolic compounds, known as hydroxybenzoic acids, that result when the gut bacteria break down aspirin and flavonoids from fruits and vegetables may contribute to colorectal cancer prevention.
New guidelines recommend aspirin use in primary prevention for people ages 40 to 70 years old who are at higher risk of a first cardiovascular event, but not for those over 70. Yet, people over 70 are at higher risks of cardiovascular events than those under 70. As a result, health care providers are understandably confused about whether or not to prescribe aspirin for primary prevention of heart attacks or strokes, and if so, to whom.
Taking a baby aspirin every day to prevent a heart attack or stroke should no longer be recommended to patients who haven’t already experienced one of these events.
Researchers investigated whether aspirin can aid in the prevention of intracranial aneurysm rupture by hindering aneurysm growth. In 146 patients harboring multiple intracranial aneurysms, the researchers found an association between aspirin use and a decreased rate of aneurysm growth.
Results from international clinical trial ‘TWILIGHT’ could change standard of care for high-risk cases